Related Experiment Videos
Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects
Fanny Monneaux1, Sylviane Muller
1CNRS, Immunologie et Chimie Thérapeutiques, Institut de Biologie Moléculaire et Cellulaire, 67000 Strasbourg, France. F.Monneaux@ibmc.u-strasbg.fr
Abstract:
The prognosis of patients with systemic lupus erythematosus has greatly improved since treatment regimens combining corticosteroids and immunosuppressive medications have been widely adopted in therapeutic strategies given to these patients. Immune suppression is evidently efficient but also leads to higher susceptibility to infectious and malignant diseases. Toxic effects and sometimes unexpectedly dramatic complications of current therapies have been progressively reported. Identifying novel molecular targets therefore remains an important issue in the treatment of lupus. The aim of this review article is to highlight emerging pharmacological options and new therapeutic avenues for lupus with a particular focus on non-antibody molecular strategies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Microorganisms in Medicine and Therapeutics
Pharmacogenomics: Identification of New Drug Targets
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...